Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 25, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Hypofractionation for prostate cancer.

Mark Ritter1, Jeffrey Forman, Patrick Kupelian

  • 1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. ritter@humonc.wisc.edu

Cancer Journal (Sudbury, Mass.)
|February 7, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Adoption and Practice Variability of Prostate Stereotactic Body Radiotherapy (SBRT) in Latin America: The Role of Continuous Education in Advancing Quality and Standardization.

Cureus·2026
Same author

Overcoming Cancer Disparities Globally: Contributions of Norman Coleman.

Disaster medicine and public health preparedness·2026
Same author

Bilateral breast treatment in a single arc using RapidArc Dynamic: A planning comparison with conventional volumetric modulated arc therapy.

Journal of applied clinical medical physics·2025
Same author

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.

JAMA oncology·2025
Same author

Gynecological Cancers Among American Indian and Alaska Native Women Living in the Upper Midwest, 1995-2019.

Women's health reports (New Rochelle, N.Y.)·2025

Hypofractionation for prostate cancer shows promise due to the cancer

Area of Science:

  • Radiation Oncology
  • Medical Physics
  • Urology

Background:

  • Hypofractionation for prostate cancer, initially for efficiency, is regaining interest.
  • A hypothesis suggests prostate cancers are more sensitive to larger radiation doses than surrounding organs.
  • This sensitivity may be linked to a low alpha/beta ratio in prostate cancer cells.

Purpose of the Study:

  • To evaluate the clinical efficacy of hypofractionation for prostate cancer.
  • To validate the hypothesis of a low alpha/beta ratio for prostate cancer.
  • To assess the potential therapeutic gain and toxicity outcomes of hypofractionation.

Main Methods:

  • Review of existing hypofractionation and brachytherapy studies.
  • Analysis of tumor control and toxicity data.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Experiment Videos

Last Updated: Jun 25, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

  • Ongoing and planned prospective and randomized trials.

    • Main Results:

    • Some analyses support a low alpha/beta ratio for prostate cancer, potentially lower than for organs at risk.
    • However, many existing studies have limitations: small patient numbers, insufficient follow-up, dose inhomogeneity (brachytherapy), or suboptimal effective doses.
    • Newer prospective trials are underway to provide more robust data.

    Conclusions:

    • The clinical efficacy of prostate cancer hypofractionation is not yet fully validated due to limitations in current evidence.
    • Prospective trials are expected to clarify the utility of hypofractionation and predictive models.
    • Hypofractionation holds potential for improved therapeutic outcomes, cost savings, and patient convenience in localized prostate cancer management.